Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelagliptin in T2DM with Severe Renal Impairment or ESRD
NCT02512068Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trelagliptin in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Started Aug 2015; status: completed.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02512068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512068.